BioWorld

Feb. 4, 2008

Denosumbab May Hold Key For an Amgen Recovery?

Although still trading near its 52-week low, Amgen Inc. got a boost at the end of January thanks to better than expected earnings and new data showing that osteoporosis drug denosumab outperformed Fosamax (alendronate, Merck & Co. Inc.) in a Phase III trial. (BioWorld Financial Watch) Read More

Money Raised Year To Date

Stock Winners and Losers For The Week

Public Financing Of Biotechnology: January 2008

Other Financings Of Public Biotechnology Companies: January 2008

Venture Capital And Other Investments In Private Biotechnology Companies: January 2008

Milestone Payments From Corporate Partners: January 2008

Money Raised By Month

Stock Indexes

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...